Posted by Michael Wonder on 15 Nov 2022
PerkinElmer announces its EONIS SCID-SMA kit is first to receive marketing authorisation by US FDA for SMA screening in newborns
14 November 2022 - Building on its contributions to newborn screening globally, PerkinElmer’s latest FDA authorised assay enables the simultaneous detection of spinal muscular atrophy and severe combined immunodeficiency.
PerkinElmer today announced that the US FDA has authorised the marketing of the EONIS SCID-SMA assay kit for in vitro diagnostic use by certified laboratories for the simultaneous detection of spinal muscular atrophy and severe combined immunodeficiency in newborns.
